Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Blind, Randomized, Parallel Arm, Phase II Proof-of-Concept Study of the Safety and Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Transplantation in Cervical Spinal Cord Injury

X
Trial Profile

A Single-Blind, Randomized, Parallel Arm, Phase II Proof-of-Concept Study of the Safety and Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Transplantation in Cervical Spinal Cord Injury

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adult neural stem cells (Primary)
  • Indications Spinal cord injuries
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Pathway
  • Sponsors StemCells
  • Most Recent Events

    • 31 May 2016 According to a StemCells Inc. media release, the Interim Analysis Data Monitoring Committee concluded that the data failed the futility criteria established for the interim analysis and recommended cessation of the study.
    • 31 May 2016 According to a StemCells, Inc. media release, status changed from recruiting to discontinued.
    • 18 Apr 2016 According to a StemCells media release, enrollment of cohort I has been complete and the company is now enrolling patients into cohort II. 19 patients have been enrolled and randomised and the enrollment is expected to be completed by the end of September 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top